Remdesivir treatment for COVID-19 shows promise at Carolina

The nation’s coronavirus task force announced positive clinical trial results for remdesivir, a treatment that was tested in the labs at the University of North Carolina at Chapel Hill.

Press the play button above to watch the video

UNC-Chapel Hill researchers are doing their part in the fight against the coronavirus that causes COVID-19.

Ralph Baric, an epidemiologist in the Gillings School of Global Public Health, heads a lab testing a broad-spectrum antiviral drug called remdesivir.

As of now, there is no FDA approved drug on the market to prevent any human coronavirus or treat associated diseases like COVID-19. “So, basically we have no weapons in our arsenal,” said Tim Sheahan, a virologist in Baric’s lab.

Six years ago, the lab partnered with the biopharmaceutical company Gilead Sciences Inc. Their goal was testing the company’s antiviral drugs to curb emerging viral diseases often overlooked by big pharmaceutical companies, said Sheahan.

Coronaviruses were of particular interest. Fast forward to today, and the intravenous drug remdesivir could potentially be a relief to this global pandemic. Just like broad-spectrum antibiotics — which can cure a wide range of bacterial infections — a broad-spectrum antiviral like remdesivir can work against genetically distinct viruses.

In animal and cell models of SAR and MERS coronavirus diseases, researchers have prevented infection and also diminished associated diseases during an ongoing infection. Sheahan said the drug has worked against every coronavirus they’ve tested so far, including the one that causes COVID-19.

As a researcher, Sheahan remains realistic about expectations.

“Though we’re optimistic that it will work, it’s possible that it won’t work,” he said. “There’s potential for success [but also] for failure.”

Not long ago, remdesivir was a hopeful solution to the 2018 Ebola outbreak. The drug was successful against the virus in the lab, but not in patients. It’s important to note, however, that Ebola is not a coronavirus.

Right now, several clinical trials are testing the drug’s efficacy and results are expected this April. If successful, Sheahan thinks it could first be given to people hospitalized with severe COVID-19 cases.

Although results thus far are promising, Sheahan points out a few factors the public should keep in mind. First, although clinical results are expected this spring, it takes much longer for a drug to get to market. Secondly, unlike the flu shot, remdesivir is delivered through an IV drip. In addition, the demand for the drug is — and will continue to be — much larger than the supply.

If successful, though, remdesivir could not only save lives of those affected with this coronavirus but also ones we have yet to face.

“Through the development of broad-spectrum drugs and vaccines, that will make a future emerging coronavirus much, much faster than what we’re dealing with today,” Sheahan said.


On April 29, the nation’s coronavirus task force announced positive clinical trial results for remdesivir.

The breakthrough treatment diminished the time to recovery from COVID-19, the disease associated with coronavirus. Testing at the Gillings School of Global Public Health set the stage for clinical trials to begin this spring as the virus spread across the globe.

“This is a game-changer for the treatment of patients with COVID-19 and provides hope to many infected,” Baric said.

The intravenous drug remdesivir could provide relief during a global pandemic that has taken the lives of nearly 60,000 Americans and sickened more than 1 million in the United States.